

ABBIE'S ARMY
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

Charity No. 1149400 (England and Wales)



ABBIE'S ARMY
FIGHT KIDS BRAIN CANCER

ABBIE'S ARMY

CONTENTS

	Page
Reference and Administrative Details	1
Report of the Trustees	2 - 7
Independent Examiner's Report	8
Statement of Financial Activities	9
Balance Sheet	10
Notes to the Financial Statements	11 - 13

ABBIE'S ARMY

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	A Mifsud (Chair) C Codner R Mifsud
Charity Number	1149400
Principal Address	MPT House Cobbs Wood Industrial Estate Brunswick Road Ashford Kent TN23 1EL
Independent Examiner	M A Wilkes FCA Azets Audit Services Greytown House 221 - 227 High Street Orpington Kent BR6 0NZ
Banker	Lloyds Bank PLC 29 Bank Street Ashford Kent TN24 8SS

ABBIE'S ARMY

REPORT OF THE TRUSTEES

The trustees present their report and examined financial statements of the charity for the year ended 31 December 2019. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK published on 16 July 2014, as amended by bulletin 1.

Public Benefit Statement

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Trust's aims and objectives and in planning future activities.

Objectives and Activities

The objectives of the charity are:

The relief of sickness and promotion of the health of children suffering with DIPG brain tumours in particular, but not exclusively by:

- 1 Promoting public awareness of the signs and symptoms of brain tumours in children and young people;
- 2 Providing funding for the development of research into practical applications for the prevention, treatment and cure of children's DIPG brain cancer.

'Our mission is to:

Raise awareness and funding for DIPG research to help overturn this 'terminal' prognosis. AND

Provide a useful resource, practical advice and support for other parents who receive this horrendous diagnosis for their child.

Our vision is a world where there is a CURE for every child diagnosed with DIPG.

This is our primary objective which guides our work and drives the charity forward on a daily basis.

What is DIPG?

DIPG or 'Diffuse Intrinsic Pontine Glioma' is the MOST FATAL form of childhood brain cancer which grows in the 'pons' area of the brainstem. DIPG presents a huge challenge, only in recent terms have we begun to biopsy this tumour safely which is finally yielding information to researchers in order to create the development of much needed targeted treatments based on an individual tumour profile. Currently DIPG is considered 'terminal at diagnosis' and represents around 15% of all brain cancer diagnoses in children. 40 UK children are affected every year. The average survival time from diagnosis is only 9 months.

Our 'mission' is to RAISE awareness and contribute much needed funds for children's DIPG brain tumour research which is so woefully underfunded. The facts are inescapable and there is no direct Government funding for DIPG research, we must provide the pre-clinical data required for translation to the patient and adoption within the clinical setting. As with any medical research development it is a long and costly endeavour.

During 2019 the charity continued to monitor its existing grants/projects made in 2018, including the study at Stanford University (US), and the continued biology/profiling support pledged to the 'Institute of Cancer Research' in Sutton (UK) for patients enrolled on the UK BIOMEDE clinical trial for DIPG, the full quantity of 40 patients is now complete. We continued to evaluate in detail the clinical landscape and funding opportunities attached to emerging therapies, still identifying new potential trends and funding needs. We have continued to build on the links with our DIPG 'community' with sadly increasing communication from new affected families for advice regarding treatment and fundraising.

ABBIE'S ARMY

REPORT OF THE TRUSTEES

Objectives and Activities (continued)

What is DIPG?

Our networks and contact base within the research community have also expanded to other UK academia. This resulted in further investments in a dedicated DIPG research position at the Institute of Cancer Research and the appointment of Elizabet Potente, and new studies with Dr Helen Fillmore at the University of Portsmouth, and Dr Francesco Crea, Head of research and the epigenetics team at The Open University.

Grant making policy

Abbie's Army are committed to raising funds and commissioning high quality and innovative medical research to find a cure for DIPG. Grants can only be funded if they fulfil our own specific criteria for funding research and if they are supported by our Scientific Advisories. Our research 'strategy' can be found published online on our website. Any grant recipients should always maximise the availability of research 'data' derived from the Grant to others with as few restrictions as possible.

We are committed to providing targeted and biologically relevant study, which contributes to combinational approaches as research is beginning to show this will be needed to be curative. We favour approaches that are medically progressive and translational with clear path to informing future clinical trials, ultimately, we must make the best decision for our donors with the limited resource that we have. Quite simply put the more we have the more we can achieve.

Abbie's Army positively welcomes the opportunity to combine efforts with other charities and fundraising groups to make a wider impact, and family groups in the 'community' have made a significant increase in donated funds in the past financial year.

Charitable objects for public benefit

In setting our objectives and planning our activities our Trustees have considered the Charity Commission's general guidance on public benefit.

As Trustees we take very seriously the responsibility to fulfil our duties, serve our objectives and deliver for public benefit our goals for supporting the effective treatment for children's DIPG brain cancer research.

Achievements and Performance in the Year

Throughout 2019 the charity continued to broaden its contact base, aiming to promote its profile locally and increase awareness throughout its UK reach using the free advertising available with social media we were fortunate to receive many public donations, mostly the result of numerous personal fundraisers taking on their own variety of events and sponsored challenges.

We were 'fortunate' to have several connections with additional families affected wishing to fundraise, local companies, schools, clubs and groups who elected us for support and donated by way of several fundraising ideas throughout the year and sponsorship from one off events. In encouraging discussion around collaboration, we received sizeable donations that permitted joint funding of the study at the University of Portsmouth and covered the dedicated DIPG research position at ICR. We are eternally grateful to the families who all made significant donations during the year in memory of their children.

ABBIE'S ARMY

REPORT OF THE TRUSTEES

Achievements and Performance in the Year (continued) Grants Awarded and Review of 2019

PDX 'Avatar' Analysis for UK BIOMEDE DIPG trial samples – Institute of Cancer Research, Sutton UK (2017 Onwards) Jones Lab

The trial commenced in the UK in April 2017 and remained open at UK treating centres as part of a European roll out to the end of 2019 – at this time it is now under continued review for those already enrolled. As the only 'adaptive' clinical trial made available in the UK and a first of its kind for DIPG, it involved an upfront biopsy and stratification of patients to various treatment arms of the trial dependent upon their genetic mutation.

We continued funding on a 'per patient' basis throughout 2019 until the first 40 patients were enrolled. 'Patient Derived Xenografts' or PDX models (also known as avatars) of individual patient disease were established for screening and testing in vitro and vivo. These were drug screened and the most efficacious agents identified will be fed back to the treating clinicians in the individual treatment centres of the patient, this resulted in some patients receiving further lines of treatment.

The models and cell lines created have been crucially used in numerous other research studies and have informed the next design of the BIOMEDE trial.

Key signalling pathways in the micro-environmental landscape of the developing pons and DIPG - University of Portsmouth UK Dr Helen Fillmore

Addressing some of the significant gaps in the understanding of the influence of tumour microenvironment and brainstem development, the fact that DIPG arises in a region and age specific nature strongly supports the suggestion of dysregulation in a postnatal neurodevelopmental process.

Key research questions focused on understanding how tumour micro-environmental elements (TME) affect tumour biology and therefore any responses to treatment will be crucial to progress. If we are to have better understanding of the origins of DIPG, precisely what controls the 'evolution' of disease and the maintenance of those malignant tissues, we may learn how to reverse or restore early key regulatory signalling pathways. The 'TME' is only one part of a DIPG treatment strategy as much as treating the 'downstream' molecular changes themselves as disease resistance develops and tumour cells carrying a particular 'target' vary during its course.

Development of H19-targeting antisense oligonucleotides for DIPG therapy – The Open University UK Dr Francesco Crea

This is also a collaborative project including other research groups. The most frequent mutation in DIPG occurs at histone H3 lysine 27 (H3K27M) resulting in widespread epigenetic dysregulation, despite global efforts no effective protein-targeting therapy has been developed for DIPG.

Long noncoding RNAs (lncRNAs) are non-protein coding transcripts, for several decades, lncRNAs have been considered non-functional transcriptional noise, more recently however numerous lncRNAs have emerged as important regulators of many biological processes. Sequencing data has revealed they represent a vast and largely uncharted region of the human transcriptome (more than 50,000 unique loci, <2% of which has been characterised).

Research already conducted by the team and by other groups has identified specific lncRNAs as drivers of cancer cell drug resistance, migration, and invasion. Antisense oligonucleotides (ASOs) are short DNA strands that bind specific RNA targets and trigger their degradation. The preferred route for ASO delivery to the central nervous system (CNS) is by intrathecal injection which results in high cerebrospinal fluid concentrations, broad distribution in the CNS and rapid cellular uptake of ASOs.

Here the team are proposing to develop lncRNA-targeting ASOs to stop DIPG proliferation, with the final goal of developing personalised therapies for this incurable disease.

ABBIE'S ARMY

REPORT OF THE TRUSTEES

Plans for the future

The charity will continue to be driven by its mission statement, its aims and objectives and ensure the best practice is delivered for our supporters.

We will continue to plan and support events to fund raise and seek out opportunities to recruit charity partners to secure more sustainable and regular income streams. We are fully aware that fundraising methods can have an impact on public opinion and the reputation of our charity, and we endeavour to self-govern effectively.

As DIPG is a specific and rare childhood cancer affecting low numbers it will remain the core of our strategy to attract and aim to invite other affected families who may want to fund raise for research purposes but cannot see the benefit in the duplication of another charity for that same purpose. We have already received support of other families who have joined us for their part to play in making an impact on the disease, collaboration is to be encouraged and, in that sense, we will proceed more quickly. We shall also more actively support the administration of fundraising campaigns for overseas trials and treatments subject to terms and conditions, to return any surplus funds to a research designation. The charity has produced a 'Parent Charter and Fundraising Guide' in this regard.

There are currently no plans to pursue the addition of paid fundraisers or PR advertising to increase revenues.

Financial Review

Income for the year amounted to £279,263 (2018: £217,173) which comes from donations by individuals and companies.

Expenditure for the year amounted to £131,558 (2018: £120,301). During the year, grants were paid amounting to £124,395 (2018: £104,713) to aid the research into DIPG.

This resulted in a surplus for the year of £147,705 (2018: £96,872).

Reserves Policy

In accordance with the Charity Commission guidance, the trustees review on a regular basis the level of income reserves that it considers appropriate. At 31 December 2019, the trustees consider it appropriate to hold no free reserves and have deemed all funds as designated funds, in support of its charitable objectives. The designated reserves at 31 December 2019 amounted to £363,448 (2018: £216,743).

Investment Policy

The investments held by the charity were inherited from previous trustees and committees. No change is foreseen by the current Board of Trustees.

Risk management

The charity Trustees have given consideration to the major risks to which the charity is exposed and satisfied themselves that those systems or procedures are established in order to manage those risks.

As a small charity working within our structure and environment our situation is not currently complex, we must however address risk particularly in relation to finances as it arises with monitoring and evaluation. Our emphasis is firmly on fund raising, so maintaining transparency and full disclosure to prevent any loss of donor confidence and adverse publicity is paramount.

COVID-19 and going concern

The Trustees in reviewing the risks facing the Charity and the steps needed to mitigate them are currently facing the challenges presented by the Covid-19 pandemic. With fundraising completely reliant on 'community' events the income for 2020 is impacted significantly.

ABBIE'S ARMY

REPORT OF THE TRUSTEES

COVID-19 and going concern (continued)

Furthermore, there is also risk that due to disruption in various academic institutions that research projects funded by us could become delayed or possibly even unable to complete.

The Charity Trustees have reflected any changes in its funding decisions based on the ongoing situation. In absence of any National UK clinical trials available for DIPG, and the unlikelihood of any being established (with the larger, usual UK trial funders severely affected) our focus had to shift to making progressive, innovative DIPG treatments available in the UK.

Further consideration was given to affected children also being unable to travel during the pandemic with the closure of International sites, even with the required funding for overseas trial for the slim 'chance' of any life extension.

The challenging conditions look set to continue into 2021, due to the lean nature of our operations and fact that the Charity does not allocate funding it does not already hold we are able to operate without change to any established charitable outputs.

However, we are restricted hugely in providing any new funding to help. We are in constant discussion with our grant holders and insisting that we do not wish to delay or extend any funding timescales when new options are so urgently needed.

We are optimistic of a gradual return to fundraising and ability to maintain sufficient income to fulfil our research aspirations. As the year progresses all efforts will be made by the Charity to ensure we may still achieve new goals with input and maximum collaboration from all other associated DIPG groups with 'research' in their own remit. Working together has never been more important.

Structure

The charity name '**Abbie's Army**' is governed by charitable Trust Deed dated 21 October 2012 which was entered onto the Register of Charities on 22 October 2012 under the registration of 1149400.

Governance and Management

The Trustees of Abbie's Army are responsible for the general control and management of the administration of the charity.

During the year the following were Trustees of the charity:

A Mifsud (Chair)
C Codner
R Mifsud

Apart from the first trustees every trustee must be appointed by a resolution of the trustees passed at a special meeting called by the appointed chairman or by at least two trustees. The governing document does not specify a minimum or maximum number of trustees.

Abbie's Army is a very small parent led charity. Its governance remains solely the responsibility of the existing member Trustees who have first-hand experience of DIPG, research knowledge of the clinical landscape and abilities to lead the charity's work.

The Trustees govern the activities of the charity and drive it forward on a daily basis, family members and friends give up their time voluntarily to administer and organise charity events, and ensure the fulfilment of our aims and objectives for 'public benefit'.

No one in connection with Abbie's Army receives payment or benefits of any kind.

ABBIE'S ARMY

REPORT OF THE TRUSTEES

Governance and Management (continued)

Our own small Scientific Advisory panel is comprised of leading experts spanning the globe in children's DIPG brain cancer research and/or administering technologies to develop new treatment strategies. Following principles of review for any grant awarded you can be assured of full impartiality from reviewers with complete independence from the charity Trustees. Advisories will not be current beneficiaries when selected to review grant applications, there will be a balance of disciplines and experience depending on the nature and monetary value of the grant.

After external expert review, they will make recommendations to ensure that Abbie's Army is fulfilling its remit to fund the most promising DIPG research projects, with its limited resource. The ultimate funding decision based on these recommendations remains with the Trustees.

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent examiner

On 7 September 2020 Group Audit Services Limited, trading as Wilkins Kennedy Audit Services, changed its name to Azets Audit Services Limited. The name they practice under is Azets Audit Services and accordingly they have signed their report in their new name.

Approved by the trustees and signed on their behalf by:

Mrs A Mifsud

Trustee

Date: 22 February 2021

ABBIE'S ARMY

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES

I report on the accounts of the Charity for the year ended 31 December 2019, which are set out on pages 9 to 13.

Responsibilities and basis of report

As the charity Trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters except that referred to in the previous paragraph have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounts records were not kept in respect of the Trust as required by section 130 of the Act; or
- 2 the accounts do not accord with those records; or
- 3 The accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

M A Wilkes FCA
Azets Audit Services

24 February 2021
Greytown House
221 - 227 High Street
Orpington
Kent BR6 0NZ

ABBIE'S ARMY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2019

		Unrestricted funds	
	Notes	2019	2018
		£	£
Income from:			
Donations		274,560	217,173
Sales of merchandise		4,703	-
Total income		279,263	217,173
Expenditure on:			
Cost of raising funds			
Costs of event staging and entry fees		215	3,852
Costs of merchandise		2,570	1,373
Just Giving / Paypal costs and membership		2,727	4,730
Cost of charitable activities			
Grants awarded	2	124,395	104,713
Website and website hosting costs		380	200
Rates		246	4,827
Sundry expenses		419	-
Depreciation		606	606
Total expenditure		131,558	120,301
Net movement in funds		147,705	96,872
Funds brought forward 1 January 2019		216,743	119,871
Funds carried forward 31 December 2019		364,448	216,743

ABBIE'S ARMY**BALANCE SHEET
AS AT 31 DECEMBER 2019**

	Notes	2019		2018	
		£	£	£	£
Fixed Assets					
Tangible assets	3		17,818		18,423
Current Assets					
Stock	4	1,000		-	
Debtors	5	56		-	
Cash at bank and in hand		<u>382,882</u>		<u>223,320</u>	
		383,938		223,320	
Creditors: amounts falling due within one year	6	<u>(37,308)</u>		<u>(25,000)</u>	
Net current assets			346,630		198,320
Net assets			<u>364,448</u>		<u>216,743</u>
Funds					
Designated funds - DIPG research			<u>364,448</u>		<u>216,743</u>

Approved by the Board of trustees on 22 February 2021 and signed on their behalf by:

Mrs A Mifsud
Trustee

R Mifsud
Trustee

ABBIE'S ARMY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1 ACCOUNTING POLICIES

1.1 Basis of preparation

Abbie's Army is a registered charity with the Charity Commission in the United Kingdom. The address of the registered office is given in the charity information on page 1 of these financial statements. The nature of the charity's operations and principal activities detailed in the Trustees' Annual Report on page 2 under the heading 'Objectives and activities'.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS 102) issued on 16 July 2014 as amended by Bulletin 1, the Financial Reporting Standard applicable in the United Kingdom (FRS 102), the Charities Act 2011, and UK Generally Accepted Practice as it applies from 1 January 2015.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity and rounded to the nearest £.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

1.2 Funds accounting

Unrestricted general funds are funds which can be used in accordance with the charitable objects at the discretion of the Trustees.

Designated funds are unrestricted funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

1.3 Income

All income is included in the Statement of Financial Activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

- Voluntary income including donations and gifts is included in full in the Statement of Financial Activities when receivable.

1.4 Expenditure

Expenditure is accounted for on an accruals basis. The irrecoverable element of VAT is included with the item of expense to which it relates.

- Costs of generating funds are those costs incurred in attracting voluntary income and staging and entering fundraising events.
- Grants payable are accounted for once the trustees have reviewed and discussed applications
- Governance costs include those incurred in the governance of the charity and are primarily associated with constitutional and statutory requirements.

1.5 Tangible fixed assets

Individual fixed assets costing £500 or more are capitalised at cost. Depreciation is provided at rates calculated to write off the cost of the assets over their

Alpacas	Not Depreciated
Fixtures and Fittings	20% Straight line

The cost of acquisition of animals is capitalised to the extent a value can be placed upon them. Subsequent births and deaths are not included on the Balance Sheet.

ABBIE'S ARMY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1 ACCOUNTING POLICIES

1.6 Stock

Stock held comprises stock provided as part of charitable activity. Stock is held at the lower of costs or net realisable value. Damaged or obsolete stock is written down as an expense.

1.7 Debtors and creditors receivable / payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

1.8 Tax

The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.

1.9 Going concern

The financial statements have been prepared on a going concern basis as the Trustees believes that no material uncertainties exist. The Trustees has considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

The Trustees in reviewing the risks facing the Charity and the steps needed to mitigate them are currently facing the challenges presented by the Covid-19 pandemic. With fundraising completely reliant on 'community' events the income for 2020 is impacted significantly. The challenging conditions look set to continue into 2021, due to the lean nature of our operations and fact that the Charity does not allocate funding it does not already hold we are able to operate without change to any established charitable outputs. However, we are restricted hugely in providing any new funding to help. We are in constant discussion with our grant holders and insisting that we do not wish to delay or extend any funding timescales when new options are so urgently needed. We are optimistic of a gradual return to fundraising and ability to maintain sufficient income to fulfil our research aspirations. As the year progresses all efforts will be made by the Charity to ensure we may still achieve new goals with input and maximum collaboration from all other associated DIPG groups with 'research' in their own remit. Working together has never been more important.

1.10 Judgements and key sources of estimation uncertainty

Accounting estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. There are no areas of judgment or key estimations.

2 GRANTS AND DONATIONS PAYABLE

	2019 £	2018 £
Grants to institutions		
Institute of Cancer Research	81,237	-
University of Portsmouth	43,158	
Monje Lab - Stanford University School of Medicine	-	104,713
	<u>124,395</u>	<u>104,713</u>

ABBIE'S ARMY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

3 TANGIBLE FIXED ASSETS	Fixtures and Fittings		Total £
	Alpacas £	£	
Cost			
As at 1 January 2019 and at 31 December 2019	16,100	3,029	19,129
Depreciation			
As at 1 January 2019 and at 31 December 2019	-	706	706
Charge for the period	-	606	606
As at 31 December 2019	-	1,312	1,312
Net Book value			
As at 31 December 2019	16,100	1,717	17,817
As at 31 December 2018	16,100	2,323	18,423
4 STOCK		2019	2018
		£	£
Stock of merchandise		1,000	-
5 DEBTORS		2019	2018
		£	£
Gift aid receivable		-	-
Other debtors		56	-
		56	-
6 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		2019	2018
		£	£
Grants payable		37,308	25,000
7 RELATED PARTY TRANSACTIONS			
During the year Mrs A Mifsud paid the following costs, as a donation, on behalf of the charity:			
		2019	2018
		£	£
Advertising		-	24
Insurance to host events		-	224

During the year Dunlop BTL Limited paid £2,915 (2018: £6,812) for the purchase of merchandise to raise funds for the charity as well as the payment of rates. R S Mifsud and Mrs A Mifsud are directors of Dunlop BTL Limited.

8 STAFF COSTS AND TRUSTEE REMUNERATION

No staff are employed by the charity.

No trustees received remuneration or were reimbursed for expenses incurred during the year (2018: £Nil).